Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-blind, Intra-individual, Crossover, Multicenter Study of the Efficacy, Safety and Tolerability of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent in the Enhanced Magnetic Resonance Angiography (MRA) in Chinese Patients

NCT00395733 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00395733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00395733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-blind, Intra-individual, Crossover, Multicenter Study of the Efficacy, Safety and Tolerability of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent in the Enhanced Magnetic Resonance Angiography (MRA) in Chinese Patients
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
October 31, 2007
Enrollment
83 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

vascular diseases